TABLE 1.
Characteristics of the study population
| Patient characteristics | |
|---|---|
| Diagnosis, n (%) | |
| Crohn's disease | 14 (74) |
| Ulcerative colitis | 5 (26) |
| Disease duration at IFX initiation (years), median (IQR) | 6 (2–9) |
| Crohn's disease location, n (%) | |
| Ileal | 0 (0) |
| Colonic | 6 (43) |
| Ileocolonic | 8 (57) |
| Isolated upper disease | 0 (0) |
| Crohn's disease behavior, n (%) | |
| Nonstricturing, nonpenetrating | 5 (36) |
| Stricturing | 4 (29) |
| Penetrating | 5 (36) |
| Crohn's disease perianal disease, n (%) | 6 (43) |
| Ulcerative colitis extent, n (%) | |
| Proctitis | 0 (0) |
| Left sided | 1 (20) |
| Extensive | 4 (80) |
| Previous abdominal surgery, n (%) | 3 (16) |
| Smoking, n (%) | 0 (0) |
| Age at conception (years), median (IQR) | 31 (27–34) |
| Clinical disease activity at last clinical visit before conception a | |
| Harvey–Bradshaw Index, median (IQR) | 3 (2–5) |
| Simple Clinical Colitis Activity Index, median (IQR) | 2.5 (0.0–5.5) |
| Number of pregnancies per patient, n (%) | |
| One pregnancy | 16 (84) |
| Two pregnancies | 2 (11) |
| Three pregnancies | 1 (5) |
| IFX therapy during pregnancy, n (%) | |
| First trimester IFX therapy | 23 (100) |
| Second trimester IFX therapy | 20 (87) |
| Third trimester IFX therapy | 7 (30) |
| Concomitant therapy during pregnancy, n (%) | |
| Thiopurines | 3 (15) |
| Steroids systemic | 1 (5) |
| Blood sample characteristics | |
|---|---|
| Trimester, n (%) | |
| Prepregnancy | 119 (69) |
| First | 16 (9) |
| Second | 18 (11) |
| Third | 7 (4) |
| Postpregnancy | 12 (7) |
| Anti‐IFX Ab positive, n (%) | 41 (30) |
| Albumin concentration (g/L), median (min‐max) | 37 (27–44) |
| C‐reactive protein (mg/dl), median (min‐max) | 2.5 (0–128) |
| Thrombocyte count (109 cells/L), median (min‐max) | 349 (217–1283) |
| White blood cell count (109 cells/L), median (min‐max) | 5 (3.5–22) |
Abbreviations: Abs, antibodies; IFX, infliximab; IQR, interquartile range.
a
<3 months from conception (median 26 days, IQR 5–52).